[Treatment of idiopathic thrombocytopenic purpura and thrombocytopenia associated with the HIV virus using anti-Rhesus immunoglobulins].
Fourteen Rhesus-positive patients with idiopathic thrombocytopenic purpura or thrombocytopenia associated with human immunodeficiency virus (HIV) infection were treated with intravenous Rhesus antibodies. The mean total dose was 6,800 micrograms administered over a 3 to 6 days' period. A significant rise in platelet count was observed in 13 of the 14 Rhesus-positive patients, but not in 3 Rhesus-negative patients used as controls. This rise was usually transient, lasting less than 3 weeks, but it persisted for more than 3 months in 2 cases. Treatment was well tolerated; transient signs of haemolysis appeared in 11 patients who did not require transfusion. Rhesus antibodies are quick-acting, the number of platelets being doubled as early as the second day of treatment. Interaction between antibody-coated red blood cells and macrophages is a possible mode of action and a feasible therapeutic approach in selected patients with autoimmune of HIV-mediated thrombocytopenia.
Durand
J M
JM
Clinique médicale B, CHU Timone, Marseille.
Lefèvre
P
P
Lafforgue
P
P
Harlé
J R
JR
Quinsat
D
D
Mongin
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006679:HIV Seropositivity / Q000150:complications*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011696:Purpura, Thrombocytopenic / Q000209:etiology / Q000628:therapy*; D012204:Rh-Hr Blood-Group System / Q000276:immunology*; D013921:Thrombocytopenia / Q000209:etiology / Q000628:therapy*
D006454:Hemoglobins; D007074:Immunoglobulin G; D012204:Rh-Hr Blood-Group System
Traitement du purpura thrombocytopénique idiopathique et des thrombocytopénies liées au VIH par les immunoglobulines anti-Rhésus.